China Bicalutamide Market Investigation Report 2010-2019

Sep 08, 2015, 13:10 ET from Research and Markets

DUBLIN, Sept. 08, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/pkdxk7/investigation) has announced the addition of the "Investigation Report on China's Bicalutamide Market, 2010-2019" report to their offering.

Originally developed by AstraZeneca and produced by some makers of generic drugs, bicalutamide is an oral non- steroidal antiandrogen. And it was approved in 1995 as a combination treatment with surgical castration for advanced prostate cancer. For patients unwilling to receive surgical castration, it is a good news that bicalutamide has since also been widely used as a monotherapy for the treatment of earlier stages of the disease.

In the US, prostate cancer is the second leading cause of male death with one in seven men suffering from it. Generally, elderly people fall victim to prostate cancer which is caused by an excess of male hormones including testosterone i.e. androgen. Therefore, the regular treatment of prostate cancer is reducing androgen levels in patients by surgical castration or ADT. In China, prostate cancer reports an incidence which ranks sixth in male malignant tumor and gradually increases with age before reaching a peak among people aged 70-80. And patients with a family history of the disease report earlier onset, among of which 43% are 55 or younger than 55.

According to this market survey, the sales value of bicalutamide in sample hospitals rose from less than CNY 14 million in 2005 to over CNY 232 million in 2014 with CAGR during this period reaching 37.6%. And AstraZeneca (Germany), Zhendong Group, Shanghai Fudan Forward Pharmaceutical Co., Ltd. , Hisun and Shanghai Zhaohui Pharmaceutical Co., Ltd. occupy the market, among of which AstraZeneca (Germany) had the largest market share of over 80% for sales value in 2014.

By the end of 2014, the number of people aged above 60 will reach 212 million and account for 15.5% of the total population in China. With aging population, the incidence of is expected to increase, which stimulates the market demand for such prostate cancer drugs as bicalutamide.

Key Topics Covered:

1 Related Concepts of Bicalutamide

2 Market Profile of Bicalutamide in China

3 Survey on Bicalutamide Sales in China, 2010-2014

4 Survey on Market Share of Major Bicalutamide Manufacturers in China, 2010-2014

5 Survey on Dosage Forms of Bicalutamide in China, 2010-2014

6 Reference Price of Bicalutamide in Chinese Hospitals in 2014

7 Major Manufacturers of Bicalutamide in Chinese Market, 2010-2014

8 Market Outlook of Bicalutamide in China, 2015-2019

Companies Mentioned

- AstraZeneca
- Shanghai Fudan Forward Pharmaceutical Co., Ltd.
- Shanghai Zhaohui Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co.,Ltd.
- Zhendong Group

For more information visit http://www.researchandmarkets.com/research/pkdxk7/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com